Adult stem cell treatment of scleroderma

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 604-610

  Tyndall, Alan ^a,c   Furst, Daniel E ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Felix Platter Spital   (Switzerland)

Author keywords

Autoimmune disease; Hematopoietic stem cell; Mesenchymal stem cell; Scleroderma; Systemic sclerosis; Transplant

Indexed keywords

COLLAGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; AUTOIMMUNITY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROVASCULAR SURGERY; MORTALITY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT STEM CELLS; ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, SYSTEMIC;

EID: 34948847074     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282e6f534     Document Type: Review

References (32)

1. van Bekkum DW. Stem cell transplantation for autoimmune disorders: preclinical experiments. Best Pract Res Clin Haematol 2004; 17:201-222.
2. Marmont AM. Stem cell transplantation for autoimmune disorders: coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17:223-232.
3. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19:643-645.
4. Sullivan KM, Furst DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol Suppl 1997; 48:1-4.
5. Tamm M, Gratwohl A, Tichelli A, et al. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis 1996; 55:779-780.
6. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60:577-584.
7. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63:974-981.
8. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100:1602-1610.
9. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study. Blood 2007; 23 April [Epub ahead of print].
10. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42:2660-2665.
11. Coghlan JG, Handler CE, Kottaridis PD. Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2007; 20:247-263. Excellent summary of cardiac aspects of HSCT risk/benefit assessment.
12. Ferri C, Giuggioli D, Sebastiani M, et al. Heart involvement and systemic sclerosis. Lupus 2005; 14:702-707.
13. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232:560-567.
14. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201:805-816.
15. Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 2007; 46:833-841. Evidence of remodelling of collagen after HSCT.
16. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006; 54:1982-1986.
17. van Laar JM, Farge D, Tyndall A. Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64:1515.
18. van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45:1187-1193.
19. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970.
20. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
21. Khorshid O, Hosing C, Bibawi S, et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 2004; 31:2513-2516.
22. Griffith LM, Pavletic SZ, Tyndall A, et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases - a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant 2006; 12:688-690.
23. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230-247.
24. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13:81-88.
25. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276:71-74.
26. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
27. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2:83-92.
28. Nakahara H, Dennis JE, Bruder SP, et al. In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res 1991; 195:492-503.
29. Sampath TK, Nathanson MA, Reddi AH. In vitro transformation of mesenchymal cells derived from embryonic muscle into cartilage in response to extracellular matrix components of bone. Proc Natl Acad Sci USA 1984; 81:3419-3423.
30. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002; 46:3349-3360.
31. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28:875-884.
32. Barry F, Boynton R, Murphy M, et al. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 2001; 289:519-524.